Cedarburg Pharmaceuticals Overview

  • Founded
  • 1998
  • Status
  • Private
  • Employees
  • 71
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $41M
Latest Deal Amount

Cedarburg Pharmaceuticals General Information


Developer of commercial small molecule active pharmaceutical ingredients (APIs) and pharmaceutical intermediates for biotech industries. The company offers synthetic active pharmaceutical ingredients (APIs), naturally derived organic molecule and semi-synthetic active pharmaceutical ingredients (APIs) development services, which comprise process development and scale-up, analytical method development, optimization and technology transfer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 870 Badger Circle
  • Grafton, WI 53024
  • United States
+1 (262) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cedarburg Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Apr-2014 $41M 000.00 0000 Completed Generating Revenue
2. Later Stage VC (Series A3) 13-Feb-2007 00.00 000.00 000.00 Completed Product Development
1. Later Stage VC (Series A) 03-Mar-2004 $7M $7M 000.00 Completed Product Development
To view Cedarburg Pharmaceuticals’s complete valuation and funding history, request access »

Cedarburg Pharmaceuticals Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 000,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series B 00,000 00.000000 00 0000 0000 00
Series A2 1,314,038,503 $0.000100 6% $0.01 $0.01 1x $0.01 52.56%
To view Cedarburg Pharmaceuticals’s complete cap table history, request access »

Cedarburg Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
John Lynch Ph.D Chief Scientific Officer
Mark Millar Director, Project Management
Paul Zizelman Ph.D Director, Scientific Operations
Charles Boland Executive Vice President
You’re viewing 4 of 7 executive team members. Get the full list »

Cedarburg Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial